Design Therapeutics, Inc.

NASDAQ:DSGN

Biotechnology

Healthcare
$9.47 +1.59%

+$0.19 today

Market cap
$606.42M
Beta
1.66
P/E (TTM)
-10.7
EPS (TTM)
-$1.13
52W Low $3.33High $17.25

Volume 0.32M

Average 0.74M

DSGN EBITDA Margin

EBITDA as a percentage of revenue.

Design Therapeutics, Inc.NASDAQ: DSGN

EBITDA Margin · Q1 FY2026 · quarter ended Mar 2026

EBITDA Margin not reported for Q1 FY2026

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
—— QoQ
Last fiscal yearDec 2025
—— YoY
LTMMar 2026
—— YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3 years———
5 years——
10 years——

EBITDA Margin history

Percent of revenue · from the income statement

No EBITDA Margin data reported for this period type.

EBITDA Margin vs competitors

How DSGN compares with its peers on the latest reported figures

DSGN Competitors Peer median
EBITDA Margin for DSGN and competitors
Company Period LTM level YoY 3-year change
PTCTPTC Therapeutics, Inc.LTM Jun 202617.2% -30.5 pp+103.9 pp
SRPTSarepta Therapeutics, Inc.LTM Mar 20265.7% +10.5 pp+34.3 pp
IONSIonis Pharmaceuticals, Inc.LTM Sep 2026-49.3% -33.5 pp+8.7 pp
WVEWave Life Sciences Ltd.LTM Mar 2026-243.2% -144.4 pp+3681.3 pp
STOKStoke Therapeutics, Inc.LTM Mar 2026-511.5% -539.6 pp+799.5 pp
DSGNDesign Therapeutics, Inc.FY2025— ——
DYNDyne Therapeutics, Inc.FY2025— ——
SLDBSolid Biosciences Inc.FY2025— ——
LRMRLarimar Therapeutics, Inc.FY2025— ——
PEPGPepGen Inc.FY2025— ——
FULCFulcrum Therapeutics, Inc.FY2025— ——
Peer median (excluding DSGN) -49.3%-33.5 pp+103.9 pp

Competitors are the stored peer set for DSGN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue0466K537K596K622K
Gross Profit0(466K)(537K)(596K)(622K)
Gross Margin—————
Research & Development24.78M48.61M57.06M44.35M59.13M
Selling, General & Admin11.05M18.98M21.13M18.03M20.34M
Operating Expenses35.83M67.13M77.65M61.79M78.85M
Depreciation & Amortization129K466K537K596K622K
EBITDA(35.4M)(62.84M)(66.33M)(48.99M)(69.17M)
EBITDA Margin—————
Operating Income(35.83M)(67.59M)(78.19M)(62.38M)(79.47M)
Operating Margin—————
Interest Income00012.8M9.68M
Interest Expense00000
Other Income / Expenses298K4.29M11.33M12.8M9.68M
Income Before Tax(35.53M)(63.31M)(66.86M)(49.59M)(69.79M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(35.53M)(63.31M)(66.86M)(49.59M)(69.79M)
Net Margin—————
EPS (Basic)(0.77)(1.14)(1.19)(0.88)(1.22)
EPS (Diluted)(0.77)(1.14)(1.19)(0.88)(1.22)
Weighted Avg Shares45.94M55.71M55.98M56.59M57.33M
Weighted Avg Shares (Diluted)45.94M55.71M55.98M56.59M57.33M

Design Therapeutics, Inc.

NASDAQ:DSGN

Intrinsic Alpha fair value

Locked

Current Price

$9.47

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.